Cargando…

Recurrence of Hepatic Encephalopathy after TIPS: Effective Prophylaxis with Combination of Lactulose and Rifaximin

Background: Transjugular intrahepatic portosystemic shunt (TIPS) implantation is an established procedure to treat portal hypertension with hepatic encephalopathy (HE) as a common complication. There is lack of evidence concerning HE prophylaxis after TIPS. Methods: N = 233 patients receiving TIPS b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seifert, Leon Louis, Schindler, Philipp, Schoster, Martin, Weller, Jan Frederic, Wilms, Christian, Schmidt, Hartmut H., Maschmeier, Miriam, Masthoff, Max, Köhler, Michael, Heinzow, Hauke, Wildgruber, Moritz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537523/ https://www.ncbi.nlm.nih.gov/pubmed/34682886 http://dx.doi.org/10.3390/jcm10204763

Ejemplares similares

TIPS Modification in the Management of Shunt-Induced Hepatic Encephalopathy: Analysis of Predictive Factors and Outcome with Shunt Modification
por: Schindler, Philipp, et al.
Publicado: (2020)

Aspirin improves transplant-free survival after TIPS implantation in patients with refractory ascites: a retrospective multicentre cohort study
por: Seifert, Leon Louis, et al.
Publicado: (2022)

Lower Ratio of Liver Volume and Body Weight Is a Negative Predictor of Survival after Transjugular Intrahepatic Portosystemic Shunt
por: Schindler, Philipp, et al.
Publicado: (2021)

Shunt-Induced Hepatic Encephalopathy in TIPS: Current Approaches and Clinical Challenges
por: Schindler, Philipp, et al.
Publicado: (2020)

Response to: Aspirin for patients after TIPS. An old dog with new tricks?
por: Seifert, Leon Louis, et al.
Publicado: (2022)

Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study
por: Paik, Yong-Han, et al.
Publicado: (2005)

Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence
por: Hudson, Mark, et al.
Publicado: (2019)

Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy
por: Wang, Zhida, et al.
Publicado: (2018)

Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis
por: Fu, Jian, et al.
Publicado: (2022)

Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota
por: Wang, Ming-Wei, et al.
Publicado: (2023)

Lactulose/rifaximin: Lack of drug effect: case report
Publicado: (2021)

Reduction in Gastrointestinal Cancers in Cirrhotic Patients Receiving Rifaximin vs Lactulose Only Therapy for Hepatic Encephalopathy
por: Patel, Ankoor H, et al.
Publicado: (2023)

Real-World Experience of the One-Year Efficacy of Rifaximin Add-On to Lactulose Is Superior to Lactulose Alone in Patients with Cirrhosis Complicated with Recurrent Hepatic Encephalopathy in Taiwan
por: Chang, Ching, et al.
Publicado: (2021)

Minimal Hepatic Encephalopathy in Indians: Psychometric Hepatic Encephalopathy Score and Inhibitory Control Test for Diagnosis and Rifaximin or Lactulose for Its Reversal
por: Pawar, Vinay B., et al.
Publicado: (2019)

Reversal of Low-Grade Cerebral Edema After Lactulose/Rifaximin Therapy in Patients with Cirrhosis and Minimal Hepatic Encephalopathy
por: Rai, Rahul, et al.
Publicado: (2015)

Repeated radioembolization in advanced liver cancer
por: Masthoff, Max, et al.
Publicado: (2020)

Analysis of failed therapy evaluations in radioembolization of primary and secondary liver cancers
por: Masthoff, Max, et al.
Publicado: (2020)

Rifaximin in the treatment of hepatic encephalopathy
por: Iadevaia, Maddalena Diana, et al.
Publicado: (2011)

Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea
por: Rezaie, Ali, et al.
Publicado: (2019)

Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial)
por: de Wit, K, et al.
Publicado: (2020)

Pictorial Representation of Illness and Self Measure (PRISM): A Novel Visual Instrument to Quantify Suffering in Liver Cirrhosis Patients and Liver Transplant Recipients
por: Kabar, Iyad, et al.
Publicado: (2018)

Rifaximin, Microbiota Biology, and Hepatic Encephalopathy
por: Peleman, Cedric, et al.
Publicado: (2016)

Primary prophylaxis of hepatic encephalopathy in decompensated cirrhosis: Low dose vs. full dose rifaximin
por: Sarwar, Shahid, et al.
Publicado: (2019)

Rifaximin as Treatment for Hepatic Encephalopathy: Some Considerations
por: Ridola, Lorenzo, et al.
Publicado: (2013)

Determination of Rifaximin Treatment Period According to Lactulose Breath Test Values in Nonconstipated Irritable Bowel Syndrome Subjects
por: Bae, Suhyun, et al.
Publicado: (2015)

Profile of Hepatic Encephalopathy in Children with Cirrhosis and Response to Lactulose
por: Sharma, Praveen, et al.
Publicado: (2011)

Multistrain probiotic and lactulose in the treatment of minimal hepatic encephalopathy
por: Shavakhi, Ahmad, et al.
Publicado: (2014)

Chronic liver disease promotes lesions of the colorectal adenoma-carcinoma sequence, independent of liver cirrhosis
por: Troschel, Amelie S., et al.
Publicado: (2019)

Intraosseous contrast administration for emergency computed tomography: A case-control study
por: Schindler, Philipp, et al.
Publicado: (2019)

Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy
por: Kimer, Nina, et al.
Publicado: (2014)

Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy
por: Jesudian, Arun B., et al.
Publicado: (2020)

Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome
por: Zhuang, Xiaojun, et al.
Publicado: (2020)

Use Of Quantitative Modelling To Elucidate The Roles Of The Liver, Gut, Kidney, And Muscle In Ammonia Homeostasis And How Lactulose And Rifaximin Alter This Homeostasis
por: Levitt, Michael D, et al.
Publicado: (2019)

Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy
por: Bajaj, Jasmohan S., et al.
Publicado: (2013)

Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese
por: Nishida, Shinya, et al.
Publicado: (2019)

Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
por: Tamai, Yasuyuki, et al.
Publicado: (2021)

Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy
por: Hayakawa, Yuka, et al.
Publicado: (2022)

Lactulose for Minimal Hepatic Encephalopathy in Patients with Extrahepatic Portal Vein Obstruction
por: Sharma, Praveen, et al.
Publicado: (2012)

Lactulose enhances neuroplasticity to improve cognitive function in early hepatic encephalopathy
por: Yang, Nan, et al.
Publicado: (2015)

The Efficacy of Lactulose for the Treatment of Hyperammonemic Encephalopathy Due to Severe Heart Failure
por: Narita, Koichi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_aus8k5u2dcret1p29923kbgcgk